{"id":"fviii-replacement","safety":{"commonSideEffects":[{"rate":"null","effect":"Inhibitor formation"},{"rate":"null","effect":"Allergic reactions"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4298010","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"FVIII replacement therapy is used to treat hemophilia A by replacing the deficient clotting factor VIII.","oneSentence":"Recombinant FVIII replacement to correct FVIII deficiency","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:33:21.476Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A"}]},"trialDetails":[{"nctId":"NCT07129343","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-10-13","conditions":"Von Willebrand Disease (VWD)","enrollment":20},{"nctId":"NCT04146376","phase":"","title":"Von Willebrand Factor in Pregnancy (VIP) Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2019-10-12","conditions":"Von Willebrand Diseases","enrollment":110},{"nctId":"NCT03587116","phase":"PHASE3","title":"A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-07-26","conditions":"Hemophilia B, Hemophilia A","enrollment":212},{"nctId":"NCT02941783","phase":"","title":"Drug Use Investigation of Kovaltry in Hemophilia A Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-30","conditions":"Hemophilia A","enrollment":230},{"nctId":"NCT07187661","phase":"NA","title":"Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-09-09","conditions":"Hemophilia, Chronic Synovitis","enrollment":25},{"nctId":"NCT07101224","phase":"","title":"Data Registry in Chinese Hemophilia A and B Patients","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2017-05-07","conditions":"Hemophilia A, Hemophilia B","enrollment":200},{"nctId":"NCT04690322","phase":"PHASE4","title":"POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-04-15","conditions":"Hemophilia A, Factor VIII","enrollment":28},{"nctId":"NCT02460458","phase":"","title":"Type 3 Von Willebrand International Registries Inhibitor Prospective Study","status":"COMPLETED","sponsor":"Fondazione Angelo Bianchi Bonomi","startDate":"2012-11-05","conditions":"Type 3 Von Willebrand's Disease","enrollment":265},{"nctId":"NCT06297486","phase":"PHASE3","title":"Study of a Gene Therapy Treatment for Hemophilia A","status":"WITHDRAWN","sponsor":"Spark Therapeutics, Inc.","startDate":"2024-03-13","conditions":"Hemophilia A","enrollment":""},{"nctId":"NCT04784988","phase":"PHASE4","title":"Intensive Replacement Treatment in Haemophilia Patients With Synovitis","status":"COMPLETED","sponsor":"Federico II University","startDate":"2022-03-01","conditions":"Hemophilia A","enrollment":64},{"nctId":"NCT06297655","phase":"PHASE3","title":"A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2024-04","conditions":"Hemophilia A","enrollment":60},{"nctId":"NCT05123326","phase":"","title":"Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-10-15","conditions":"Hepatic Vein Thromboses, Hepatic Venous Outflow Obstruction, Portal Vein Thrombosis","enrollment":300},{"nctId":"NCT01311648","phase":"PHASE3","title":"BAY81-8973 Pediatric Safety and Efficacy Trial","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-06-09","conditions":"Haemophilia A","enrollment":94},{"nctId":"NCT03876301","phase":"","title":"Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants","status":"COMPLETED","sponsor":"Spark Therapeutics, Inc.","startDate":"2019-01-21","conditions":"Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders","enrollment":25},{"nctId":"NCT05636163","phase":"","title":"Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratio in Predicting the Incidence of Nausea and Vomiting","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2022-12-15","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT04715100","phase":"","title":"Pain and Joint Status With Psychosocial Factors in Patients With Hemophilia","status":"UNKNOWN","sponsor":"Investigación en Hemofilia y Fisioterapia","startDate":"2022-04-05","conditions":"Hemophilia Arthropathy","enrollment":60},{"nctId":"NCT03603275","phase":"","title":"Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry","status":"TERMINATED","sponsor":"Bayer","startDate":"2018-08-06","conditions":"Hemophilia A","enrollment":3},{"nctId":"NCT05281185","phase":"PHASE4","title":"Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2021-07-01","conditions":"Severe Hemophilia A Without Inhibitor","enrollment":15},{"nctId":"NCT02234323","phase":"PHASE3","title":"An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2015-01-12","conditions":"Hemophilia A","enrollment":108},{"nctId":"NCT02546622","phase":"","title":"ATHN 2: Factor Switching Study","status":"COMPLETED","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2015-09","conditions":"Hemophilia","enrollment":310},{"nctId":"NCT02392156","phase":"","title":"Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes","status":"TERMINATED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2015-07","conditions":"Hemophilia A, Hemophilia B","enrollment":3},{"nctId":"NCT02577614","phase":"PHASE1","title":"FEIBA and Use of Blood Products in Cardiac Surgery","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2016-02","conditions":"Cardiovascular Disease","enrollment":12},{"nctId":"NCT04372173","phase":"","title":"An Evaluation of Clotting Factor Activity Before and After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2018-02-01","conditions":"Arthroplasty, Replacement, Coagulation Factors","enrollment":30},{"nctId":"NCT02306694","phase":"PHASE3","title":"Prospective Biomarkers of Bone Metabolism in Hemophilia A","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2014-12","conditions":"Hemophilia, Bone Disease","enrollment":16},{"nctId":"NCT02996942","phase":"","title":"Key Aspects of Medical Practice in Patients With Haemophilia A","status":"WITHDRAWN","sponsor":"Lund University","startDate":"2012-07","conditions":"Joint Disease","enrollment":""},{"nctId":"NCT03405337","phase":"","title":"Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-14","conditions":"Hemophilia A","enrollment":160},{"nctId":"NCT02697370","phase":"PHASE4","title":"Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A","status":"COMPLETED","sponsor":"Hampshire Hospitals NHS Foundation Trust","startDate":"2013-04","conditions":"Severe Haemophilia A","enrollment":20},{"nctId":"NCT00557908","phase":"","title":"The Von Willebrand Disease (VWD) International Prophylaxis Study","status":"COMPLETED","sponsor":"Skane University Hospital","startDate":"2007-06","conditions":"Von Willebrand Disease","enrollment":105},{"nctId":"NCT02476942","phase":"","title":"A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05-26","conditions":"Hemophilia A","enrollment":221},{"nctId":"NCT01571934","phase":"","title":"Inhibitor Development in Patients With Hemophilia A Undergoing Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-11","conditions":"Hemophilia A","enrollment":30},{"nctId":"NCT00621673","phase":"PHASE4","title":"Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A","status":"TERMINATED","sponsor":"Bayer","startDate":"2006-05","conditions":"Hemophilia A","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":260,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"FVIII Replacement","genericName":"FVIII Replacement","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant FVIII replacement to correct FVIII deficiency Used for Hemophilia A.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}